CA2475206A1 - Inhibiteurs de map-kinase comme regulateurs d'expression antigenique associe aux tumeurs - Google Patents

Inhibiteurs de map-kinase comme regulateurs d'expression antigenique associe aux tumeurs Download PDF

Info

Publication number
CA2475206A1
CA2475206A1 CA 2475206 CA2475206A CA2475206A1 CA 2475206 A1 CA2475206 A1 CA 2475206A1 CA 2475206 CA2475206 CA 2475206 CA 2475206 A CA2475206 A CA 2475206A CA 2475206 A1 CA2475206 A1 CA 2475206A1
Authority
CA
Canada
Prior art keywords
cells
tumor
antigen
cancer cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2475206
Other languages
English (en)
Inventor
James T. Kurnick
Paul J. Durda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2475206A1 publication Critical patent/CA2475206A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à des procédés pour l'identification d'agents modulateurs de l'expression des antigènes spécifiques de tumeurs dans des cellules tumorales. L'invention a également trait à des agents et des compositions pharmaceutiques contenant de tels agents modulateurs de l'expression des antigènes spécifiques de tumeurs dans des cellules tumorales. Par conséquent l'invention est particulièrement utile, entre autres, pour le traitement de sujets atteints de tumeurs solides autologues présentant des cellules exprimant, ou pouvant être induites à exprimer, des antigènes spécifiques de tumeurs. Une catégorie de matières selon l'invention est constituée par d'agents de régulation positive d'antigènes spécifiques de tumeurs. Ces agents comprennent des modulateurs de la cascade de signalisation de MAPK/ERKL, et plus spéficiquement des modulateurs de l'activité de MEK1/2 et de ERK1/2.
CA 2475206 2002-02-15 2003-02-18 Inhibiteurs de map-kinase comme regulateurs d'expression antigenique associe aux tumeurs Abandoned CA2475206A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35758602P 2002-02-15 2002-02-15
US60/357,586 2002-02-15
PCT/US2003/004786 WO2004087941A1 (fr) 2002-02-15 2003-02-18 Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs

Publications (1)

Publication Number Publication Date
CA2475206A1 true CA2475206A1 (fr) 2003-08-15

Family

ID=33130319

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2475206 Abandoned CA2475206A1 (fr) 2002-02-15 2003-02-18 Inhibiteurs de map-kinase comme regulateurs d'expression antigenique associe aux tumeurs

Country Status (4)

Country Link
EP (1) EP1509614A4 (fr)
AU (1) AU2003222221A1 (fr)
CA (1) CA2475206A1 (fr)
WO (1) WO2004087941A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
EP2074226A2 (fr) * 2006-09-19 2009-07-01 Novartis AG Biomarqueurs de modulation cible, efficacité, diagnostic et/ou pronostic pour les inhibiteurs de la raf
WO2009069668A1 (fr) * 2007-11-28 2009-06-04 National University Corporation Nagoya University Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2011156970A1 (fr) * 2010-06-18 2011-12-22 Xu Zhiheng Utilisations d'un mtea dans le diagnostic et le traitement d'une tumeur maligne
CN103403187A (zh) * 2011-01-18 2013-11-20 艾沃锐斯特基因有限公司 结肠直肠癌复发的预后特征
WO2013001372A2 (fr) * 2011-06-30 2013-01-03 University Of Oslo Procédés et compositions pour inhiber l'activation des lymphocytes t régulateurs
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
DK2971045T3 (da) 2013-03-13 2019-09-16 Health Research Inc Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
WO2016168264A1 (fr) * 2015-04-13 2016-10-20 Kiromic, Llc Méthodes et compositions pour traiter un cancer avec des cellules dendritiques
CN114686433A (zh) * 2020-12-28 2022-07-01 华中科技大学 一种小鼠三阴型原发胶质母细胞瘤细胞株及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
EP1365796A2 (fr) * 2000-09-01 2003-12-03 Van Andel Institute Inhibition de la voie de la proteine mapkkk: une strategie therapeutique selective contre les melanomes

Also Published As

Publication number Publication date
AU2003222221A1 (en) 2004-10-25
EP1509614A1 (fr) 2005-03-02
WO2004087941A1 (fr) 2004-10-14
EP1509614A4 (fr) 2007-09-12

Similar Documents

Publication Publication Date Title
US20250101079A1 (en) T cell receptors with mage-b2 specificity and uses thereof
Schwitalle et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers
Silva et al. Glycans as immune checkpoints: removal of branched N-glycans enhances immune recognition preventing cancer progression
Carrascal et al. Sialyl Tn‐expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells
Hiraoka et al. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis
KR102722572B1 (ko) 암치료법의 치료 효능 및 암 예후 예측용 방법 및 조성물
US12496298B2 (en) Natural killer cells
CN106659912B (zh) Dickkopf2(Dkk2)抑制作用抑制肿瘤形成
EP1509614A1 (fr) Inhibiteurs de la proteine kinase associee aux membranes en tant que regulateurs de l'expression de l'antigene specifique de tumeurs
WO2009014565A2 (fr) Procédés pour le diagnostic et le traitement des astrocytomes
Wang et al. Expression of the human Sda β-1, 4-N-acetylgalactosaminyltransferase II gene is dependent on the promoter methylation status
EP1232178A2 (fr) Compositions et methodes permettant de reguler l'expression des antigenes specifiques de tumeurs
KR20220095112A (ko) Mdsc 활성 저해 약물의 선별 방법
KR20230004458A (ko) Apc-결핍 암의 치료를 위한 방법 및 조성물
Nakayama et al. NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytes
CN1840707B (zh) 基于免疫耐受树突细胞筛选免疫耐受相关疾病的基因rgs1的方法
AU2022246174A1 (en) Methods and compositions for t-cell coculture potency assays and use with cell therapy products
Voigt et al. CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses
EP2249159A1 (fr) Identification des marqueurs associés aux tumeurs pour diagnostic et thérapie
US20100068142A1 (en) Melanoma repopulating cells
CN1840709B (zh) 筛选与鉴定治疗免疫耐受相关疾病功能基因serpinh1的方法
CN104640568A (zh) 用于治疗mds的cd95信号传导途径的抑制剂
JP2013147464A (ja) 医薬組成物
Schröder Tumor-specific CD8 T cells in a primary human breast carcinoma: a detailed analysis
HK1154593A (en) Differential in tumour gene products and use of same

Legal Events

Date Code Title Description
FZDE Dead